X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1069) 1069
Publication (136) 136
Book Review (24) 24
Book Chapter (8) 8
Conference Proceeding (2) 2
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nab-paclitaxel (967) 967
index medicus (604) 604
oncology (555) 555
humans (509) 509
chemotherapy (504) 504
pancreatic cancer (378) 378
cancer (346) 346
gemcitabine (344) 344
female (265) 265
paclitaxel (255) 255
metastasis (220) 220
survival (204) 204
albumin-bound paclitaxel (185) 185
phase-iii trial (185) 185
aged (174) 174
middle aged (172) 172
paclitaxel - administration & dosage (170) 170
antineoplastic combined chemotherapy protocols - therapeutic use (168) 168
breast cancer (163) 163
pharmacology & pharmacy (162) 162
animals (159) 159
male (159) 159
pancreatic neoplasms - drug therapy (159) 159
pancreatic neoplasms - pathology (152) 152
care and treatment (150) 150
albumins - administration & dosage (141) 141
treatment outcome (141) 141
cancer therapies (134) 134
docetaxel (133) 133
patients (125) 125
therapy (124) 124
adenocarcinoma (123) 123
adult (122) 122
drug therapy (122) 122
folfirinox (118) 118
tumors (116) 116
nanoparticles (113) 113
deoxycytidine - analogs & derivatives (109) 109
antineoplastic agents (104) 104
antimitotic agents (103) 103
trial (102) 102
combination (101) 101
paclitaxel - therapeutic use (99) 99
clinical trials (98) 98
research (97) 97
1st-line therapy (94) 94
medicine & public health (94) 94
health aspects (91) 91
paclitaxel - adverse effects (91) 91
neoplasms. tumors. oncology. including cancer and carcinogens (86) 86
albumins - therapeutic use (84) 84
albumins - adverse effects (83) 83
antineoplastic agents - therapeutic use (83) 83
medical prognosis (83) 83
carboplatin (82) 82
analysis (81) 81
prognosis (81) 81
breast-cancer (79) 79
phase-ii trial (79) 79
ductal adenocarcinoma (77) 77
breast neoplasms - drug therapy (75) 75
deoxycytidine - administration & dosage (75) 75
antineoplastic combined chemotherapy protocols - adverse effects (73) 73
article (70) 70
gastroenterology & hepatology (70) 70
neoplasm metastasis (70) 70
disease-free survival (69) 69
dosage and administration (68) 68
mice (68) 68
surgery (68) 68
aged, 80 and over (67) 67
albumin (67) 67
usage (67) 67
plus gemcitabine (64) 64
review (63) 63
drug delivery systems (62) 62
toxicity (62) 62
cremophor-free (61) 61
efficacy (61) 61
adenocarcinoma - drug therapy (59) 59
hematology, oncology and palliative medicine (59) 59
open-label (59) 59
cisplatin (57) 57
medical research (56) 56
metastases (56) 56
neoplasm staging (55) 55
cancer research (54) 54
development and progression (54) 54
expression (54) 54
solvent-based paclitaxel (54) 54
antineoplastic agents - administration & dosage (52) 52
drugs (52) 52
metastatic breast cancer (52) 52
studies (52) 52
cell line, tumor (51) 51
lung neoplasms - drug therapy (51) 51
neoplasms - drug therapy (50) 50
neutropenia (49) 49
patient outcomes (49) 49
breast neoplasms - pathology (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1042) 1042
German (13) 13
Japanese (5) 5
Korean (5) 5
Russian (4) 4
French (3) 3
Italian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medicine, ISSN 0025-7974, 03/2019, Volume 98, Issue 9, p. e14758
Treatment options for patients with relapsed/refractory small cell lung cancer (R/R SCLC) are limited, and the efficacy of salvage therapies for heavily... 
PHASE-III TRIAL | paclitaxel | MEDICINE, GENERAL & INTERNAL | ETOPOSIDE | CISPLATIN | BEVACIZUMAB | TOPOTECAN | nab-paclitaxel | COMPARING AMRUBICIN | small cell lung cancer | chemotherapy
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2015, Volume 76, Issue 4, pp. 699 - 712
nab-paclitaxel demonstrates improved clinical efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types. This study explored... 
Cremophor EL | Medicine & Public Health | Nanoparticle | Albumin | Oncology | Cancer Research | Taxane | Pharmacology/Toxicology | nab -paclitaxel | nab-paclitaxel | COLONY-STIMULATING FACTOR | SOLID TUMORS | PANCREATIC-CANCER | NONLINEAR PHARMACOKINETICS | PHASE-III TRIAL | BREAST-CANCER | ONCOLOGY | ENDOTHELIAL-CELLS | IN-VIVO | PHARMACOLOGY & PHARMACY | SOLVENT-BASED PACLITAXEL | CREMOPHOR EL MICELLES | Endothelium, Vascular - cytology | Paclitaxel - metabolism | Pancreatic Neoplasms - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Nanoparticles - chemistry | Humans | Capillary Permeability - drug effects | Endothelium, Vascular - drug effects | Paclitaxel - pharmacokinetics | Endosomes - metabolism | Serum Albumin, Human | Drug Delivery Systems | Pancreatic Neoplasms - drug therapy | Tissue Distribution | Antineoplastic Agents, Phytogenic - administration & dosage | Human Umbilical Vein Endothelial Cells - cytology | Endosomes - drug effects | Tubulin Modulators - administration & dosage | Tubulin Modulators - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Biological Transport - drug effects | Antineoplastic Agents, Phytogenic - therapeutic use | Carcinoma - pathology | Paclitaxel - administration & dosage | Serum Albumin - chemistry | Antineoplastic Agents, Phytogenic - pharmacokinetics | Carcinoma - drug therapy | Human Umbilical Vein Endothelial Cells - drug effects | Microinjections | Tubulin Modulators - pharmacokinetics | Pancreatic Neoplasms - pathology | Cells, Cultured | Endosomes - pathology | Paclitaxel - therapeutic use | Tubulin Modulators - therapeutic use | Xenograft Model Antitumor Assays | Animals | Endothelium, Vascular - metabolism | Mice, Nude | Cell Line, Tumor | Endothelium, Vascular - pathology | Carcinoma - metabolism | Infusions, Intravenous | Serum Albumin - metabolism | Antimitotic agents | Dimethyl sulfoxide | Exhibitions | Permeability | Antineoplastic agents | Tumors | Index Medicus | Original
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2014, Volume 54, Issue 10, pp. 1097 - 1107
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 07/2015, Volume 62, Issue 7, pp. 1214 - 1221
Journal Article
BREAST CANCER RESEARCH, ISSN 1465-5411, 09/2019, Volume 21, Issue 1, pp. 100 - 9
Background Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall... 
MULTICENTER | EFFICACY | SAFETY | Neoadjuvant | OPEN-LABEL | Nab-paclitaxel | CHEMOTHERAPY | RCB | PLUS DOCETAXEL | ONCOLOGY | T-DM1 | Ado-trastuzumab emtansine | Lapatinib | HER2
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2013, Volume 109, Issue 4, pp. 926 - 933
Journal Article
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 06/2017, Volume 34, Issue 6, pp. 1180 - 1186
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. 568 - 576
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of... 
SPARC protein | Paclitaxel | Pancreatic adenocarcinoma | Breast cancer | Nab-paclitaxel
Journal Article